Intellia Therapeutics (NTLA) Net Cash Flow (2016 - 2026)

Intellia Therapeutics has reported Net Cash Flow over the past 12 years, most recently at -$17.5 million for Q1 2026.

  • Quarterly Net Cash Flow rose 68.01% to -$17.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Mar 2026, up 105.12% year-over-year, with the annual reading at -$35.2 million for FY2025, 6.25% up from the prior year.
  • Net Cash Flow was -$17.5 million for Q1 2026 at Intellia Therapeutics, up from -$39.8 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $385.7 million in Q4 2022 and troughed at -$229.4 million in Q1 2023.
  • The 5-year median for Net Cash Flow is -$6.9 million (2022), against an average of $1.4 million.
  • Year-over-year, Net Cash Flow tumbled 1629.85% in 2023 and then skyrocketed 459.45% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $385.7 million in 2022, then tumbled by 84.61% to $59.4 million in 2023, then increased by 15.7% to $68.7 million in 2024, then crashed by 157.91% to -$39.8 million in 2025, then skyrocketed by 56.08% to -$17.5 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Net Cash Flow are -$17.5 million (Q1 2026), -$39.8 million (Q4 2025), and $37.2 million (Q3 2025).